Thiery-Vuillemin, A., Saad, F., Armstrong, A. J., Oya, M., Vianna, K. C. M., Ozguroglu, M., … Clarke, N. W. (2022). Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 40).

Thiery-Vuillemin, Antoine, Fred Saad, Andrew J. Armstrong, Mototsugu Oya, Karina Costa Maia Vianna, Mustafa Ozguroglu, Craig Gedye, et al. “Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 40, 2022.

Thiery-Vuillemin A, Saad F, Armstrong AJ, Oya M, Vianna KCM, Ozguroglu M, et al. Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial. In: JOURNAL OF CLINICAL ONCOLOGY. 2022.

Thiery-Vuillemin, Antoine, et al. “Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial.” JOURNAL OF CLINICAL ONCOLOGY, vol. 40, no. 16, 2022.

Thiery-Vuillemin A, Saad F, Armstrong AJ, Oya M, Vianna KCM, Ozguroglu M, Gedye C, Buchschacher GL, Lee JY, Emmenegger U, Navratil J, Virizuela JA, Salazar A, Maillet D, Uemura H, Kim J, Lukacs E, Barker L, Degboe AN, Clarke NW. Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial. JOURNAL OF CLINICAL ONCOLOGY. 2022.